^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | AFM24 (EGFR inhibitor, CD16A agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase 1/2a study of AFM24 and Atezolizumab in patients with advanced and metastatic cancers Estudio de fase 1/2a de AFM24 y atezolizumab en pacientes con cáncer avanzado y metastásico
Excerpt:
...Archived paraffin-embedded tumor tissue is acceptable for EGFR determination, otherwise a fresh tumor biopsy must be performed.-EXP-4: patients with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior TKI approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib.5) ECOG Performance Status (PS) 0 or 16) Adequate organ function as determined by:a. ...
Trial ID:
Source:
Title:
Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers
Excerpt:
...- Advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥ prior TKI approved for EGFR mutated NSCLC....
Trial ID:
Less C2 evidence
Source:
Title:
Leveraging innate immunity with AFM24, a novel CD16A and epidermal growth factor receptor (EGFR) bispecific innate cell engager: Interim results for the non-small cell lung cancer (NSCLC) cohort.
Published date:
05/25/2023
Excerpt:
The Phase 2a expansion phase is evaluating 480 mg AFM24 in patients with EGFR mutant NSCLC...Best objective response in 10 evaluable patients was confirmed partial response in 1 patient (change from baseline –45%); 4 patients exhibited stable disease, 1 was confirmed....AFM24 demonstrated clinical activity and acceptable safety in heavily pretreated patients with EGFR mutant NSCLC.
DOI:
10.1200/JCO.2023.41.16_suppl.2533
Trial ID:
